Hwp document

CURRICULUM VITAE
NAME: Doo-Man Kim, M.D. (Professor)
ADDRESS:
Div. of Endocrinology & Metabolism, Dept. of Internal Medicine College of Medicine, Hallym University, Kangdong Sacred Heart Hospital, 445 Kil-Dong, Kangdong-Gu,
Seoul 134-701, Korea
Phone: 82-2-2224-2575
Fax: 82-2-478-6925
E-mail: dm@hallym.or.kr, dmjmsy@kornet.net
EDUCATION:
M.D. Chonnam National University, College of Medicine, Gwangju, SouthKorea B.S. Biochemistry, Kyunghee University, College of Medicine, Seoul, SouthKorea PROFESSIONAL ACTIVITIES:
Internship, National Medical Center, Seoul, South Korea Residency, Department of Internal Medicine, National Medical Center, SouthKorea Military Service, Surgeon General (Captain) Clinical Fellow, Endocrinology section, Department of Internal Medicine, SeoulNational University Hospital, Seoul, South Korea Staff Physician, Dept. of Internal Medicine, Daehan Hospital, South Korea Assistant Professor, Dept. of Internal Medicine, Hallym University, College ofMedicine, South Korea Associate Professor, Department of Internal Medicine, Hallym University,College of Medicine, South Korea FIELDS OF INTEREST:
1. The role of AGE in diabetic complication2. The role of hypoglycemia on the development of cardiovascular disease in type 2 diabetes 3. Diagnosis of tertiary adrenal insufficiency and steroid hormone replacement SOCIETIES:
1. Director, Committe of Education, Korean Diabetes Association; Jan 2008~ Dec 20092. Editor in chief, Endocrinology and Metabolism (Official journal of Korea Endocrine ONGOING PROJECTS IN 2011:
BOEHRINGER INGELHEIM [10-098]
A multicentre, international, randomised, parallel group, double blind study to
evaluate cardiovascular safety of linagliptin versus glimepiride in patients whti
type 2 diabetes mellitus at high cardiovascular risk. The CAROLINA trial
Principal Investigator
31,218,750won / 31,218,750won (2011)
CHOONGWAE PHARMA [10-003]
Observational study of LIVALO tab for research of safety information by
concomitant administration with oral antidiabetic agents in T2DM patients.
Principal Investigator
1,725,000won / 1,725,000won (2011)
DONG-A PHARMACEUTICAL [10-095]
A randomized, duoble-blind, placebo-controlled, therapeutic exploratory clinical
trial to investigate the efficacy and safety of DA-1229 after oral administration
in patients with type 2 diabetes who have inadequate glycaemic control on diet
and exercise.
Principal Investigator
18,975,000won / 18,975,000won (2011)
QUINTILES [10-065]
A multi-center, randomized, open-label, active-controlled study to compare the
efficacy, safety and tolerability of taspoglutide (RO5073031) versus insulin
glargine in insulin-naïve type 2 diabetic patients inadequately controlled with
metformin and sulfonylurea combination therapy.
Principal Investigator
22,425,000won / 22,425,000won (2011)
BOEHRINGER INGELHEIM [10-056]
A phase III randomised, double-blind, placebo-controlled, parallel group,
efficacy and safety study of BI 10773 (10mg, 25mg) administered orally , once
daily over 24 weeks in patients with type 2 diabetes mellitus with insufficient
glycaemic control despite treatment with metformin alone of metformin in
combination with a sulfonylurea.
Principal Investigator
16,825,000won / 16,825,000won (2011)
CJ CHEILJEDANG [10-110]
A randomized, double-blind, multicenter clinical trial to evaluate the efficacy
and safety of CJ-30001 and CJ-30002 in patients with type 2 diabetes and
inadequate glycemic control ; Phase III study
Principal Investigator
24,426,000won / 24,426,000won (2011)
CHOONGWAE PHARMA [11-019]
A multicenter, randomized, double blind, double dummy, active-controlled,
therapeutic confirmatory trial (phase 3) to evaluate the efficacy and safety of
CWP-0403 compared with Sitagliptin added to ongoing metformin therapy in patients
with type 2 DM insufficiently controlled with metformin alone
Principal Investigator
43,987,500won / 43,987,500won (2011)
YUHAN [11-076]
Phase II clinical trial to investigate the efficacy, safety and pharmacokinetics ofYH14617 after once weekly or biweekly administration in patients with type 2Diabetes Mellitus.
Principal Investigator33,139,000won / 33,139,000won (2011) CHOONGWAE PHARMA [11-018]
A multicenter, randomized, double blind, placebo controlled, therapeutic confirmatory
trial (phase 3) to evaluate the efficacy and safety of CWP-0403 in type 2 DM patients
Principal Investigator
18,917,500won / 18,917,500won (2011)
BOEHRINGER INGELHEIM [10-106]
A phase III double-blind, extension, placebo-controlled parallel group safety and
efficacy trial of BI 10773 ( 10 and 25mg once daily ) and sitagliptin (100mg once
dailly) given for minimum 76 weeks (incl. 24 weeks of preceding trial ) as
monotherapy or with different back-ground therapies in patients with type 2 diabetes
mellitus previously completing tiral 1245.19, 1245.20 or 1245.23)
Principal Investigator
18,000,000won / 18,000,000won (2011)
PUBLICATIONS IN 2011:
KCI Accredited Journal
(Candidated Journal for Accreditation)
I. SCI(E); First author or Corresponding author
II. SCI(E); Co-author
III. KCI Accredited Journal (Candidated Journal for Accreditation); First author or
Corresponding author
IV. KCI Accredited Journal (Candidated Journal for Accreditation); Co-author
1. SY Rhee, S Chon, MK Kwon, IB Park, KJ Ahn, IJ Kim, SH Kim, HW Lee, KS Koh, DM Kim, SH Baik,
KW Lee, MS Nam, YS Park, JT Woo, YS Kim, Prevalence of Chronic Complications in Korean
Patients with Type 2 Diabetes Mellitus Based on the Korean National Diabetes Program.
Diabetes and Metabolism Journal Vol. 35(5), PP. 504~512, 2011

Source: http://eng.hallym.or.kr/file/06-6.Doo-Man%20Kim.pdf